Viatris (VTRS) Other Accumulated Expenses (2019 - 2026)
Viatris (VTRS) posted Other Accumulated Expenses of $2.9 billion for Q2 2026, down 7.97% on a QoQ basis from $3.1 billion in Q1 2026, and down 21.52% year-over-year from $3.7 billion in Q2 2025.
Analysis
Viatris (VTRS) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Viatris has reported Other Accumulated Expenses for 8 years, with the latest figure at $2.9 billion in Q2 2026.
- On a quarterly basis, Other Accumulated Expenses fell 21.52% year-over-year to $2.9 billion in Q2 2026; TTM through Jun 2026 was $2.9 billion, a 21.52% decrease from a year earlier, with the FY2025 full-year figure at $3.3 billion, down 11.86% from the prior year.
- Other Accumulated Expenses was $2.9 billion for Q2 2026 at Viatris, down from $3.1 billion in the prior quarter.
- The five-year high for Other Accumulated Expenses was $4.4 billion in Q1 2022, with the low at $2.9 billion in Q2 2026.
- Average Other Accumulated Expenses over 5 years is $3.5 billion, with a median of $3.4 billion recorded in 2022.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses dropped 27.87% in 2023, then gained 16.27% in 2024.
- Over 5 years, Other Accumulated Expenses stood at $3.4 billion in 2022, then slipped by 1.37% to $3.4 billion in 2023, then climbed by 9.75% to $3.7 billion in 2024, then dropped by 11.86% to $3.3 billion in 2025, then slipped by 12.26% to $2.9 billion in 2026.
- The last three Other Accumulated Expenses figures came in at $2.9 billion (Q2 2026), $3.1 billion (Q1 2026), and $3.3 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.88 Bn |
| Mar 31, 2026 | 3.13 Bn |
| Dec 31, 2025 | 3.28 Bn |
| Sep 30, 2025 | 3.62 Bn |
| Jun 30, 2025 | 3.67 Bn |
| Mar 31, 2025 | 3.63 Bn |
| Dec 31, 2024 | 3.72 Bn |
| Sep 30, 2024 | 3.86 Bn |
| Jun 30, 2024 | 3.23 Bn |
| Mar 31, 2024 | 3.28 Bn |
| Dec 31, 2023 | 3.39 Bn |
| Sep 30, 2023 | 3.32 Bn |
| Jun 30, 2023 | 3.05 Bn |
| Mar 31, 2023 | 3.19 Bn |
| Dec 31, 2022 | 3.44 Bn |
| Sep 30, 2022 | 3.50 Bn |
| Jun 30, 2022 | 3.81 Bn |
| Mar 31, 2022 | 4.43 Bn |
| Dec 31, 2021 | 4.62 Bn |
| Sep 30, 2021 | 4.63 Bn |